BioSpace News Archive

The diabetes drugs market size valued at USD 66 billion in 2023 is projected to grow at a CAGR of 6.7% from 2023 to 2032, reaching an estimated value of USD 118 billion by 2032.

AriBio Co., Ltd. (AriBio) announces approval of the Investigational New Drug (IND) application by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the initiation of the Phase 3 Polaris-AD trial in China of AR1001 in early Alzheimer’s Disease (AD) on May 11th, 2024.

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2024.

BioAtla, Inc. announced its financial results for the first quarter ended March 31, 2024, and provided highlights on its clinical programs.

Korro Bio, Inc., a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, reported financial results for the first quarter of 2024 and provided an update on its recent progress and anticipated milestones.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Merit Medical Systems, Inc., a global leader of healthcare technology, announced US Food and Drug Administration 510 clearance for its Siege Vascular Plug. Merit also announced the launch of its Bearing nsPVA Express Prefilled Syringe in the United States and Australia.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies

Affimed N.V. announced the publication of an abstract for the annual congress of the European Hematology Association, taking place in Madrid, Spain, June 13 – 16, 2024.

Saghmos Therapeutics, Inc., a privately held biopharmaceutical company, announced that the Japanese Patent Office has issued Japanese Patent No. 7474463 for its Phase 3-ready product, ST-62516, a cardiorenal metabolic modulator.